Bibliography
- RONG S, BODESCOT M, BLAIR D et al.: Tumorigenicity of the Met proto-oncogene and the gene for hepatocyte growth factor. Mol. Cell. Biol. (1992) 12:5152–5158.
- TRUSOLINO L, COMOGLIO PM: Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat. Rev. Cancer (2002) 2:289–300.
- •• An excellent review of HGF and c-Metbiology and description of their roles in tumorigenesis.
- BIRCHMEIER C, BIRCHMEIER W, GHERARDI E, VAN DE WOUDE GF: Met, metastasis, motility and more. Nat. Rev. MoL Cell. Biol. (2003) 4:915–925.
- SATTLER M, MA PC, SALGIA R: Therapeutic targeting of the receptor tyrosine kinase Met. Cancer Treat. Res. (2004) 119:121–138.
- BUSSOLINO F, DI RENZO MF, ZICHE M et al.: Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J. Cell Biol. (1992) 119:629–641.
- • Early evidence indicating that HGF and c-Met affect angiogenesis.
- SAUCIER C, KHOURY H, LAI K-MV et al.: The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis. Proc. NatL Acad. Sci. USA (2004) 101:2345–2350.
- • Convincing use of genetic mouse models to demonstrate that HGF induces VEGF expression during angiogenesis.
- SATTLER M, PRIDE YB, MA P et al.: A novel small molecule Met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. (2003) 63:5462–6459.
- CHRISTENSEN JG, SCHRECK R, BURROWS J et al.: A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. (2003) 63:7345–7355.
- •• A convincing demonstration of thepotential efficacy of a small-molecule c-Met kinase inhibitor using in vitro and in vivo models.
- CAO B, SU Y, OSKARSSON M et a/.: Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. USA (2001) 98:7443–7448.
- MATSUMOTO K, NAKAMURA T: NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci. (2003) 94:321–327.
- • A complete review of NK4 biology and its anti-angiogenic and antitumour effects.
- CHAN AM-L, RUBIN JS, BOTTARO DP, HIRSCHFIELD DW, CHEDID M, AARONSON SA: Identification of a competitive HGF antagonist encoded by an alternative transcript. Science (1991) 254:1382–1385.
- LADNER RC, SATO AK, GORZELANY J, DE SOUZA M: Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discov. Today (2004) 15:525–529.
- • A good review describing progress in identifying peptide antagonists for drug development.
- MA PC, SCHAEFER E, CHRISTENSEN JG, SALGIA R: A selective small molecule c-MET inhibitor, PHA665752, cooperates with rapamycin. Clin. Cancer Res. (2005) 11:2312–2319.
Websites
- http://www.exelixis.com/ index.asp?secPagerelease&re1184 Exelhcis Initiates Phase I Trial for Anticancer Compound XL 880